U.S. Drug-Price Linking Creates New Access Questions for Canada

New United States drug-pricing agreements are designed to reduce what state Medicaid programs pay for selected branded medicines by linking their net costs to lower prices in other developed countries. The policy does not directly change Canadian drug prices. It does, however, create a new commercial incentive for manufacturers to reconsider how they set list prices, negotiate confidential discounts, sequence product launches and manage supply in countries used as price references.

The immediate Canadian question is therefore about future access decisions—not evidence that pharmacy acquisition costs or patient prices have already increased. The issue gained renewed attention in a CBC News report published September 27, 2026, which brought together Canadian policy and pharmacy perspectives. The primary records below show why the concern is plausible, while also showing how much remains uncertain.

Key takeaways

• The White House says agreements with 26 manufacturers extend most-favoured-nation pricing to every U.S. state Medicaid program, the District of Columbia and Puerto Rico.
• Canada appears in a 19-country reference basket used in related U.S. Medicare pricing models studied in The Lancet.
• Lower U.S. prices do not automatically produce higher Canadian prices; manufacturers would still operate within Canadian price review, reimbursement and competition rules.
• The practical risks are indirect: delayed launches, higher proposed list prices, smaller confidential rebates or supply decisions intended to protect prices in the U.S.
• Publicly released agreements remain incomplete and redacted, so the size and timing of any Canadian effect cannot yet be established.

What changed in the United States

On September 18, 2026, the White House announced that all state Medicaid programs would receive most-favoured-nation pricing under agreements with pharmaceutical manufacturers. The administration said 26 companies covering about 90% of the branded U.S. market had signed agreements and projected substantial savings. Those savings figures are administration estimates, not independently observed Canadian outcomes.

The Medicaid agreements sit beside related U.S. Medicare models known as GLOBE and GUARD. A 2026 cohort study in The Lancet modelled those Medicare approaches using price data from 19 reference countries, including Canada. The study estimates potential U.S. savings; it does not demonstrate that Canadian prices have risen.

What the released agreements show—and do not show

Public Citizen obtained Pfizer and Eli Lilly agreement documents through freedom-of-information requests and posted them on September 19. The documents confirm that company-specific terms exist, but large portions are redacted and only a fraction of the announced agreements are publicly available. That makes it difficult to determine how manufacturers will respond in each country or product market.

The policy creates a theoretical incentive to avoid a low foreign price being used to reduce a U.S. benchmark. A company could respond by seeking a higher launch price, offering a smaller confidential rebate, delaying a launch or changing supply. Each option has commercial and regulatory constraints, and none should be reported as an established Canadian outcome without product-specific evidence.

Canada’s safeguards still apply

The Patented Medicine Prices Review Board (PMPRB) reviews patented medicine prices in Canada to ensure they are not excessive. The PMPRB does not approve medicines, decide whether provincial or territorial plans reimburse them, or set pharmacy professional fees. Public plans and the pan-Canadian Pharmaceutical Alliance also negotiate coverage and prices through separate processes.

These layers mean a U.S. policy cannot simply dictate the Canadian price at the pharmacy counter. They do not, however, eliminate the possibility that manufacturers may change launch timing, pricing proposals, rebate strategy or supply decisions before a medicine reaches Canadian patients.

Practice guidance for pharmacists

• Avoid premature claims: tell patients that no automatic Canadian price increase has been established.
• Separate systems clearly: distinguish U.S. Medicaid and Medicare policy from Canadian federal price review, public-plan reimbursement and private insurance.
• Monitor access signals: watch for manufacturer launch delays, formulary-listing changes, unusual allocation messages and verified shortage reports.
• Document real barriers: record product-specific acquisition problems, rejected claims and clinically meaningful delays rather than attributing them to the U.S. policy without evidence.
• Use authoritative updates: check PMPRB, Health Canada, the pan-Canadian Pharmaceutical Alliance and provincial plan notices before changing counselling or workflow.
• Offer practical alternatives: when access changes occur, discuss covered therapeutic options and continuity plans with prescribers and patients within scope.

What happens next

The most useful Canadian indicators will be product-level: proposed list prices, launch dates, public-plan negotiations, supply decisions and any documented change in availability. Until those signals emerge, this is an access risk to monitor—not a confirmed nationwide price increase.

Sources

• What Trump’s “most favoured nation” drug pricing policy might mean for Canadians — CBC News, September 27, 2026.
• President Trump Extends Most Favored Nation Drug Pricing to Every Medicaid Program in America — The White House, September 18, 2026.
• FOIA Documents: Trump-Pharma MFN Drug Pricing Deals — Public Citizen, September 19, 2026.
• Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study — The Lancet, September 13, 2026.
• Mandate and Jurisdiction — Patented Medicine Prices Review Board, Government of Canada.